Exact Mass: 1056.514098
Exact Mass Matches: 1056.514098
Found 68 metabolites which its exact mass value is equals to given mass value 1056.514098,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PIP(20:2(11Z,14Z)/6 keto-PGF1alpha)
C49H86O20P2 (1056.5187415999999)
PIP(20:2(11Z,14Z)/6 keto-PGF1alpha) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/6 keto-PGF1alpha), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(6 keto-PGF1alpha/20:2(11Z,14Z))
C49H86O20P2 (1056.5187415999999)
PIP(6 keto-PGF1alpha/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(6 keto-PGF1alpha/20:2(11Z,14Z)), in particular, consists of one chain of 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(20:2(11Z,14Z)/TXB2)
C49H86O20P2 (1056.5187415999999)
PIP(20:2(11Z,14Z)/TXB2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/TXB2), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(TXB2/20:2(11Z,14Z))
C49H86O20P2 (1056.5187415999999)
PIP(TXB2/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(TXB2/20:2(11Z,14Z)), in particular, consists of one chain of Thromboxane B2 at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide
(3beta,21beta,22alpha)-3-(3-O-angeloyl-beta-D-glucopyranosyloxy)-21,22-dihydroxy-28-beta-sophorosyloxy-16-oxoolean-12-ene|terminaliaside A
cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside G
alternoside XIV|chichipegenin 22-O-tigloyl-3-O-beta-D-glucopyranosyl(1->3)-beta-D-glucuronopyranosyl-28-O-beta-D-glucopyranoside
11(S)-convolvulinolic acid 11-O-beta-D-glucopyranosyl-(1->3)-O-[4-O-2S-methylbutyryl-alpha-L-rhamnopyranosyl-(1->4)-]-O-alpha-L-rhamnopyranosyl-(1->4)-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-fucopyranoside-1,3-ester|quamoclin V
26-O-beta-D-glucopyranosyl-22alpha-methoxyfurosta-5,25(27)-diene-1beta,3beta,26-triol 1-O-alpha-L-rhamnopyranosyl-(1->2)-3-acetyl-4-[(2S,3S )-2-hydroxy-3-methylpentanoyl]-alpha-L-arabinopyranoside
cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoanteisopentadecanoic acid)|maribasin B
3-O-beta-D-galactopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 28-O-angeloyl-A1-barrigenol
cynaforrogenin A 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-alpha-L-cymaropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-oleandropyranoside|cynaforroside P
3-O-beta-D-glucopyranosyl-(1->2)-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucuronopyranosyl-22-O-beta,beta-dimethylacryloyl-A1-barrigenol
cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoisopentadecanoic acid)|maribasin A
3-O-beta-D-glucopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 22-O-angeloyl-A1-barrigenol
3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide)
1,6-Bis-O-[(1,1-dimethylethyl)diphenylsilyl]-beta-D-fructofuranosyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-alpha-D-glucopyranoside
PIP(20:2(11Z,14Z)/6 keto-PGF1alpha)
C49H86O20P2 (1056.5187415999999)
PIP(6 keto-PGF1alpha/20:2(11Z,14Z))
C49H86O20P2 (1056.5187415999999)
MART-1 (26-35) (human) (TFA)
MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.
3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
2-{[8a-({[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-9,10-dihydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl 2-methylbut-2-enoate
3-[1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9s)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
3-[(3r,7r,10r,13r,16s,19s,22s,27ar)-1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-[(9s)-9-methylundecyl]-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-8-[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}pentanediimidic acid
3-[1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-(9-methylundecyl)-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9r)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
n-{5-benzyl-6,13,16,21-tetrahydroxy-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}pentanediimidic acid
(4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-10-({4,5-dihydroxy-3-[(3-hydroxy-6-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-9-formyl-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
(3s,4ar,6ar,6bs,8ar,10s,12as,14ar,14br)-3-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-{[(2e)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-4,4,6a,11,11,14b-hexamethyl-1h,2h,3h,4ah,5h,6h,7h,7ah,8h,9h,10h,12h,12ah,14h,14ah-cyclopropa[i]picene-8a-carboxylic acid
C56H80O19 (1056.5293530000001)
3-[9-dodecyl-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
(2r,3r,4s,5r,6r)-2-{[(3s,4ar,6ar,6bs,8as,9r,10r,12as,14ar,14br)-8a-({[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-9,10-dihydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl (2z)-2-methylbut-2-enoate
(5r,8s,11r,12s,15s,18s,19s,22r)-18-[(1e,3e,5s,6s)-6-(acetyloxy)-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-8-benzyl-15-(3-carbamimidamidopropyl)-3,6,9,13,16,20-hexahydroxy-1,5,12,19-tetramethyl-2-methylidene-25-oxo-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid
C53H72N10O13 (1056.5280062000002)
7-{[5-({4-hydroxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-4b-methyl-2-(2-methylfuran-3-yl)-2,3,4,4a,5,6,7,8,10,10a-decahydrophenanthren-1-one
6-{[7,8-dihydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-9-[(3-methylbut-2-enoyl)oxy]-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-4-hydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxane-2-carboxylic acid
(3s,4ar,6ar,6bs,7as,8ar,10s,12as,14ar,14br)-3-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-{[(2e)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-4,4,6a,11,11,14b-hexamethyl-1h,2h,3h,4ah,5h,6h,7h,7ah,8h,9h,10h,12h,12ah,14h,14ah-cyclopropa[i]picene-8a-carboxylic acid
C56H80O19 (1056.5293530000001)
3-[(3r,7r,10r,13r,16s,19s,22s,27ar)-1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-(9-methylundecyl)-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
3-[1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(9-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid
n-{2-benzyl-15-ethylidene-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-2-({1-hydroxy-2-[(1,2,3-trihydroxypropylidene)amino]propylidene}amino)-4-(4-hydroxyphenyl)butanimidic acid
3-{[3-({3,4-dihydroxy-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-{[3-(4-methoxyphenyl)prop-2-enoyl]oxy}-4,4,6a,11,11,14b-hexamethyl-1h,2h,3h,4ah,5h,6h,7h,7ah,8h,9h,10h,12h,12ah,14h,14ah-cyclopropa[i]picene-8a-carboxylic acid
C56H80O19 (1056.5293530000001)
(3s,4ar,6ar,6bs,7ar,8ar,10s,12as,14ar,14br)-3-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-{[(2e)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-4,4,6a,11,11,14b-hexamethyl-1h,2h,3h,4ah,5h,6h,7h,7ah,8h,9h,10h,12h,12ah,14h,14ah-cyclopropa[i]picene-8a-carboxylic acid
C56H80O19 (1056.5293530000001)